FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600303476> ?p ?o ?g. }

• W2600303476 endingPage "33275" @default.
• W2600303476 startingPage "33265" @default.
• W2600303476 abstract "// Hai Hu 1, 2, * , Lei-Lei Wu 4, * , Ting Han 1, 2 , Meng Zhuo 1, 2 , Wang Lei 1, 2 , Jiu-Jie Cui 2, 3 , Feng Jiao 2, 3 , Li-Wei Wang 1, 2, 3 1 Department of Medical Oncology and Pancreatic Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China 2 Shanghai Key Laboratory of Pancreatic Disease, Shanghai 201620, China 3 Department of Medical Oncology and Pancreatic Cancer Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200000, China 4 School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 201620, China * These authors contributed equally to this work Correspondence to: Feng Jiao, email: jiao_f@yeah.net Li-Wei Wang, email: yzwlw@hotmail.com Keywords: immunohistochemistry, FXR, Sp1, pancreatic cancer, prognosis Received: December 02, 2016      Accepted: February 28, 2017      Published: March 28, 2017 ABSTRACT Bile acids (BAs) was critical in the initiation and progression of various tumors. However, their prognostic significance in pancreatic cancer was still illusive. In the present study, the expression and biological significance of FXR, a major receptor of BAs, in the lethal disease were evaluated in mRNA and protein levels. We found that FXR protein was elevated in the cancerous tissues, which was significantly higher than the adjacent tissues ( p < 0.05). Meanwhile, our data showed that FXR was positively correlated with primary tumor location ( p = 0.04) and poor survival ( p = 0.002). Finally, COX regression model indicated that FXR protein was an independent prognostic factor ( p = 0.01; HR = 2.15; 95% CI 1.27-3.63). Consistently, we also found a significant difference of FXR expression between the high and low groups in mRNA level ( p < 0.001), and that high FXR expression confers a poor prognosis ( p < 0.001). More importantly, the correlation assay showed that FXR was positively correlated Sp1 in both protein ( r = 0.351, p = 0.008) and mRNA levels ( r = 0.263, p < 0.01), with the simultaneously high expression indicated the worst prognosis on protein ( p < 0.001) and mRNA levels ( p < 0.001). Additionally, we also showed that FXR was elevated in the pancreatic cancer cells responsible for proliferation and migration. Overall, the data suggested co-high expression of the two factors was an independent prognostic factor ( p < 0.001; HR = 3.27; 95% CI 1.86–5.76). Based on these data, we proposed a model to link FXR to Sp1, which included triggered FXR, p38/MAPK and/or PI3K/AKT signaling and phosphorylated Sp1, to illustrate the potential crosstalk between the two factors." @default.
• W2600303476 created "2017-04-07" @default.
• W2600303476 creator A5000441787 @default.
• W2600303476 creator A5013488344 @default.
• W2600303476 creator A5036246350 @default.
• W2600303476 creator A5041701154 @default.
• W2600303476 creator A5047704890 @default.
• W2600303476 creator A5055723755 @default.
• W2600303476 creator A5073216396 @default.
• W2600303476 creator A5081109406 @default.
• W2600303476 date "2017-03-28" @default.
• W2600303476 modified "2023-10-12" @default.
• W2600303476 title "Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray" @default.
• W2600303476 cites W1076956034 @default.
• W2600303476 cites W1931508686 @default.
• W2600303476 cites W1976647466 @default.
• W2600303476 cites W1978546305 @default.
• W2600303476 cites W1986943142 @default.
• W2600303476 cites W1987672874 @default.
• W2600303476 cites W1990353372 @default.
• W2600303476 cites W2016303022 @default.
• W2600303476 cites W2019253502 @default.
• W2600303476 cites W2044686871 @default.
• W2600303476 cites W2063767041 @default.
• W2600303476 cites W2074469807 @default.
• W2600303476 cites W2075171279 @default.
• W2600303476 cites W2075890816 @default.
• W2600303476 cites W2080332077 @default.
• W2600303476 cites W2091983867 @default.
• W2600303476 cites W2100399645 @default.
• W2600303476 cites W2120500136 @default.
• W2600303476 cites W2123105952 @default.
• W2600303476 cites W2126275851 @default.
• W2600303476 cites W2152080897 @default.
• W2600303476 cites W2157769714 @default.
• W2600303476 cites W2163483059 @default.
• W2600303476 cites W2170552969 @default.
• W2600303476 cites W2186781473 @default.
• W2600303476 cites W2191241037 @default.
• W2600303476 cites W2193181899 @default.
• W2600303476 cites W2328205009 @default.
• W2600303476 cites W2341590147 @default.
• W2600303476 cites W2412946572 @default.
• W2600303476 cites W2531817426 @default.
• W2600303476 cites W4362218836 @default.
• W2600303476 doi "https://doi.org/10.18632/oncotarget.16633" @default.
• W2600303476 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5464866" @default.
• W2600303476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28402278" @default.
• W2600303476 hasPublicationYear "2017" @default.
• W2600303476 type Work @default.
• W2600303476 sameAs 2600303476 @default.
• W2600303476 citedByCount "12" @default.
• W2600303476 countsByYear W26003034762017 @default.
• W2600303476 countsByYear W26003034762018 @default.
• W2600303476 countsByYear W26003034762019 @default.
• W2600303476 countsByYear W26003034762020 @default.
• W2600303476 countsByYear W26003034762021 @default.
• W2600303476 countsByYear W26003034762022 @default.
• W2600303476 crossrefType "journal-article" @default.
• W2600303476 hasAuthorship W2600303476A5000441787 @default.
• W2600303476 hasAuthorship W2600303476A5013488344 @default.
• W2600303476 hasAuthorship W2600303476A5036246350 @default.
• W2600303476 hasAuthorship W2600303476A5041701154 @default.
• W2600303476 hasAuthorship W2600303476A5047704890 @default.
• W2600303476 hasAuthorship W2600303476A5055723755 @default.
• W2600303476 hasAuthorship W2600303476A5073216396 @default.
• W2600303476 hasAuthorship W2600303476A5081109406 @default.
• W2600303476 hasBestOaLocation W26003034761 @default.
• W2600303476 hasConcept C121608353 @default.
• W2600303476 hasConcept C126322002 @default.
• W2600303476 hasConcept C143998085 @default.
• W2600303476 hasConcept C193270364 @default.
• W2600303476 hasConcept C2780210213 @default.
• W2600303476 hasConcept C502942594 @default.
• W2600303476 hasConcept C50382708 @default.
• W2600303476 hasConcept C71924100 @default.
• W2600303476 hasConceptScore W2600303476C121608353 @default.
• W2600303476 hasConceptScore W2600303476C126322002 @default.
• W2600303476 hasConceptScore W2600303476C143998085 @default.
• W2600303476 hasConceptScore W2600303476C193270364 @default.
• W2600303476 hasConceptScore W2600303476C2780210213 @default.
• W2600303476 hasConceptScore W2600303476C502942594 @default.
• W2600303476 hasConceptScore W2600303476C50382708 @default.
• W2600303476 hasConceptScore W2600303476C71924100 @default.
• W2600303476 hasIssue "20" @default.
• W2600303476 hasLocation W26003034761 @default.
• W2600303476 hasLocation W26003034762 @default.
• W2600303476 hasLocation W26003034763 @default.
• W2600303476 hasLocation W26003034764 @default.
• W2600303476 hasOpenAccess W2600303476 @default.
• W2600303476 hasPrimaryLocation W26003034761 @default.
• W2600303476 hasRelatedWork W110742162 @default.
• W2600303476 hasRelatedWork W121009447 @default.
• W2600303476 hasRelatedWork W2043890160 @default.
• W2600303476 hasRelatedWork W2341353074 @default.
• W2600303476 hasRelatedWork W2384938748 @default.
• W2600303476 hasRelatedWork W2401514044 @default.
• W2600303476 hasRelatedWork W2752933131 @default.

• next